CTRI/2018/03/012393Completed未知
An open-label, single centre, pilot clinical study to evaluate the effect of CurQfen on brain function in Middle aged to Elderly population by Quantitative EEG analysis and cognitive assessment tests.
Akay Flavours and Aromatics Private Limited0 sites6 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 6
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1)Age 35-65 Years ( Both Inclusive)
- •2)Male and Female Subjects
- •3)Subjects in general good health.
- •4)Subjects with a MMSE score between 25 â?? 30
Exclusion Criteria
- •EXCLUSION CRITERIA
- •1)Subjects with a education qualification less than higher secondary level
- •2)Subjects who are not familiar with computer/internet use.
- •3)Subject with dementia/related memory loss illness
- •4)Subjects diagnosed with learning difficulty such as dyslexia or dyspraxia
- •5)Suffering from any form of clinically diagnosed disease, including:
- •oMajor mental illness (current or previous episode with hospitalization)
- •oChronic fatigue syndrome
- •oLiver disease
- •oDiabetes mellitus
- •oHeart disease or myocardial infarction
- •ounderwent brain surgery
- •owho have a central nervous system illness
- •oneurological lesion
- •6)Subjects with a known allergy to herbal products
- •7)Subjects with abnormal biochemical or haematological values
- •8)Subjects with abnormal blood pressure
- •9)Pregnant or Lactating Women
- •10)Any condition that in Opinion of the Investigator, does not justify the Subjectsâ?? participation in the study.
Investigators
Similar Trials
Completed
Not Applicable
The effect of Rhodiola rosea Extract WS 1375 on attention and mental resource allocatioISRCTN29449049Dr. Willmar Schwabe GmbH & Co. KG (Germany)50
Active, not recruiting
Not Applicable
Medical research trial for testing drug treatment of alpha-Mannosidosisalpha-MannosidosisMedDRA version: 17.1Level: LLTClassification code 10032658Term: Other specified disorders of carbohydrate transport and metabolismSystem Organ Class: 100000004850EUCTR2014-003950-15-DKZymenex A/S
Completed
Not Applicable
A single centre, open label trial investigating the absorption, metabolism and excretion of somapacitan after single subcutaneous dosing in healthy male subjectsgroeihormoondeficientiegrowth hormone deficiencyNL-OMON42854ovo Nordisk A/S7
Active, not recruiting
Phase 1
A study to investigate a new medication, NI-0501, in children with the disease systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH)EUCTR2016-004223-23-FRovimmune SA10
Active, not recruiting
Phase 1
A study to investigate a new medication, NI-0501, in children with the disease systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH)Macrophage activation syndrome / Secondary hemophagocytic lymphohistiocytosis (MAS/sHLH) in patients with Systemic Juvenile Idiopathic Arthritis (sJIA)MedDRA version: 21.1Level: LLTClassification code 10053867Term: Macrophage activation syndromeSystem Organ Class: 100000004870EUCTR2016-004223-23-NLovimmune SA10